RT Journal Article SR Electronic T1 Most intended management changes after 68Ga-DOTATATE PET/CT are implemented JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP jnumed.117.192450 DO 10.2967/jnumed.117.192450 A1 Jérémie Calais A1 Johannes Czernin A1 Matthias Eiber A1 Wolfgang Peter Fendler A1 Jeannine Gartmann A1 Anthony Heaney A1 Andrew Hendifar A1 Joseph Pisegna A1 Joel Randolph Hecht A1 Edward Wolin A1 Roger Slavik A1 Pawan Gupta A1 Andrew Quon A1 Christiaan Schiepers A1 Martin Allen-Auerbach A1 Ken Herrmann YR 2017 UL http://jnm.snmjournals.org/content/early/2017/05/03/jnumed.117.192450.abstract AB Background: In this prospective referring physician based survey, we investigated the definite clinical impact of 68Ga-DOTATATE positron emission tomography / computed tomography (PET/CT) on managing patients with neuroendocrine tumors (NET). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire prior to the scan (Q1) to indicate the treatment plan without PET/CT information; one immediately after review of the imaging report to denote intended management changes (Q2); and one 6 months later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96/130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended treatment management changes (Q2) in 48/96 patients (50%). These changes were finally implemented (Q3) in 36/48 patients (75%). Q3 responses have been confirmed in all patients with available electronic chart (36/96; 38%). Conclusion: This prospective study confirms a significant impact of 68Ga-DOTATATE PET/CT on intended management of patients with NET (50% of changes) and notably demonstrates a high implementation rate (75%) of these intended management changes.